Background: There is a potential role of choline in cardiovascular and cerebrovascular disease through its involvement in lipid and one-carbon metabolism.Objective: We evaluated the associations of plasma choline and choline-related compounds with cardiometabolic risk factors, history of cardiovascular disease, and cerebrovascular pathology.Design: A cross-sectional subset of the Nutrition, Aging, and Memory in Elders cohort who had undergone MRI of the brain (n = 296; mean ± SD age: 73 ± 8.1 y) was assessed. Plasma concentrations of free choline, betaine, and phosphatidylcholine were measured with the use of liquid-chromatography-stable-isotope dilution-multiple-reaction monitoring-mass spectrometry. A volumetric analysis of MRI was used to determine the cerebrovascular pathology (white-matter hyperintensities and small- and large-vessel infarcts). Multiple linear and logistic regression models were used to examine relations of plasma measures with cardiometabolic risk factors, history of cardiovascular disease, and radiologic evidence of cerebrovascular pathology. Results: Higher concentrations of plasma choline were associated with an unfavorable cardiometabolic risk-factor profile [lower high-density lipoprotein (HDL) cholesterol, higher total homocysteine, and higher body mass index (BMI)] and greater odds of large-vessel cerebral vascular disease or history of cardiovascular disease but lower odds of small-vessel cerebral vascular disease. Conversely, higher concentrations of plasma betaine were associated with a favorable cardiometabolic risk-factor profile [lower low-density lipoprotein (LDL) cholesterol and triglycerides] and lower odds of diabetes. Higher concentrations of plasma phosphatidylcholine were associated with characteristics of both a favorable cardiometabolic risk-factor profile (higher HDL cholesterol, lower BMI, lower C-reactive protein, lower waist circumference, and lower odds of hypertension and diabetes) and an unfavorable profile (higher LDL cholesterol and triglycerides). Conclusion: Choline and its metabolites have differential associations with cardiometabolic risk factors and subtypes of vascular disease, thereby suggesting differing roles in the pathogenesis of cardiovascular and cerebral large-vessel disease compared with that of small-vessel disease.
Background: There is a potential role of choline in cardiovascular and cerebrovascular disease through its involvement in lipid and one-carbon metabolism.Objective: We evaluated the associations of plasma choline and choline-related compounds with cardiometabolic risk factors, history of cardiovascular disease, and cerebrovascular pathology.Design: A cross-sectional subset of the Nutrition, Aging, and Memory in Elders cohort who had undergone MRI of the brain (n = 296; mean ± SD age: 73 ± 8.1 y) was assessed. Plasma concentrations of free choline, betaine, and phosphatidylcholine were measured with the use of liquid-chromatography-stable-isotope dilution-multiple-reaction monitoring-mass spectrometry. A volumetric analysis of MRI was used to determine the cerebrovascular pathology (white-matter hyperintensities and small- and large-vessel infarcts). Multiple linear and logistic regression models were used to examine relations of plasma measures with cardiometabolic risk factors, history of cardiovascular disease, and radiologic evidence of cerebrovascular pathology. Results: Higher concentrations of plasma choline were associated with an unfavorable cardiometabolic risk-factor profile [lower high-density lipoprotein (HDL) cholesterol, higher total homocysteine, and higher body mass index (BMI)] and greater odds of large-vessel cerebral vascular disease or history of cardiovascular disease but lower odds of small-vessel cerebral vascular disease. Conversely, higher concentrations of plasma betaine were associated with a favorable cardiometabolic risk-factor profile [lower low-density lipoprotein (LDL) cholesterol and triglycerides] and lower odds of diabetes. Higher concentrations of plasma phosphatidylcholine were associated with characteristics of both a favorable cardiometabolic risk-factor profile (higher HDL cholesterol, lower BMI, lower C-reactive protein, lower waist circumference, and lower odds of hypertension and diabetes) and an unfavorable profile (higher LDL cholesterol and triglycerides). Conclusion:Choline and its metabolites have differential associations with cardiometabolic risk factors and subtypes of vascular disease, thereby suggesting differing roles in the pathogenesis of cardiovascular and cerebral large-vessel disease compared with that of small-vessel disease.
Authors: Heather R Millard; Solomon K Musani; Daniel T Dibaba; Sameera A Talegawkar; Herman A Taylor; Katherine L Tucker; Aurelian Bidulescu Journal: Eur J Nutr Date: 2016-08-22 Impact factor: 5.614
Authors: Will D King; Vikki Ho; Linda Dodds; Sherry L Perkins; R Ian Casson; Thomas E Massey Journal: Mol Biol Rep Date: 2012-04-24 Impact factor: 2.316
Authors: Simone J P M Eussen; Per M Ueland; Robert Clarke; Henk J Blom; Willibrord H L Hoefnagels; Wija A van Staveren; Lisette C P G M de Groot Journal: Br J Nutr Date: 2007-05-31 Impact factor: 3.718
Authors: Michael Lever; Peter M George; Jane L Elmslie; Wendy Atkinson; Sandy Slow; Sarah L Molyneux; Richard W Troughton; A Mark Richards; Christopher M Frampton; Stephen T Chambers Journal: PLoS One Date: 2012-05-23 Impact factor: 3.240
Authors: Yanping Li; Dong D Wang; Stephanie E Chiuve; JoAnn E Manson; Walter C Willett; Frank B Hu; Lu Qi Journal: Diabetes Care Date: 2015-02 Impact factor: 19.112
Authors: Geoffrey A Walford; Yong Ma; Clary Clish; Jose C Florez; Thomas J Wang; Robert E Gerszten Journal: Diabetes Date: 2016-02-09 Impact factor: 9.461
Authors: Miranda J Spratlen; Maria Grau-Perez; Jason G Umans; Joseph Yracheta; Lyle G Best; Kevin Francesconi; Walter Goessler; Teodoro Bottiglieri; Mary V Gamble; Shelley A Cole; Jinying Zhao; Ana Navas-Acien Journal: Environ Res Date: 2018-09-27 Impact factor: 6.498
Authors: Benjamin C Fu; Meredith A J Hullar; Timothy W Randolph; Adrian A Franke; Kristine R Monroe; Iona Cheng; Lynne R Wilkens; John A Shepherd; Margaret M Madeleine; Loïc Le Marchand; Unhee Lim; Johanna W Lampe Journal: Am J Clin Nutr Date: 2020-06-01 Impact factor: 7.045
Authors: Miranda J Spratlen; Maria Grau-Perez; Jason G Umans; Joseph Yracheta; Lyle G Best; Kevin Francesconi; Walter Goessler; Poojitha Balakrishnan; Shelley A Cole; Mary V Gamble; Barbara V Howard; Ana Navas-Acien Journal: Environ Int Date: 2018-10-12 Impact factor: 9.621
Authors: Zhilei Shan; Clary B Clish; Simin Hua; Justin M Scott; David B Hanna; Robert D Burk; Sabina A Haberlen; Sanjiv J Shah; Joseph B Margolick; Cynthia L Sears; Wendy S Post; Alan L Landay; Jason M Lazar; Howard N Hodis; Kathryn Anastos; Robert C Kaplan; Qibin Qi Journal: J Infect Dis Date: 2018-09-22 Impact factor: 5.226
Authors: Xiong-Fei Pan; Jae Jeong Yang; Xiao-Ou Shu; Steven C Moore; Nicholette D Palmer; Marta Guasch-Ferré; David M Herrington; Sei Harada; Heather Eliassen; Thomas J Wang; Robert E Gerszten; Demetrius Albanes; Ioanna Tzoulaki; Ibrahim Karaman; Paul Elliott; Huilian Zhu; Lynne E Wagenknecht; Wei Zheng; Hui Cai; Qiuyin Cai; Charles E Matthews; Cristina Menni; Katie A Meyer; Loren P Lipworth; Jennifer Ose; Myriam Fornage; Cornelia M Ulrich; Danxia Yu Journal: Am J Clin Nutr Date: 2021-09-01 Impact factor: 8.472
Authors: Marta Guasch-Ferré; Frank B Hu; Miguel Ruiz-Canela; Mònica Bulló; Estefanía Toledo; Dong D Wang; Dolores Corella; Enrique Gómez-Gracia; Miquel Fiol; Ramon Estruch; José Lapetra; Montserrat Fitó; Fernando Arós; Lluís Serra-Majem; Emilio Ros; Courtney Dennis; Liming Liang; Clary B Clish; Miguel A Martínez-González; Jordi Salas-Salvadó Journal: J Am Heart Assoc Date: 2017-10-28 Impact factor: 5.501